58 related articles for article (PubMed ID: 25865734)
1. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Dain B; Pergolizzi JV; Raffa R; Ripa SR
Pain Pract; 2016 Apr; 16(4):473-85. PubMed ID: 25865734
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.
Gordon A; Rashiq S; Moulin DE; Clark AJ; Beaulieu AD; Eisenhoffer J; Piraino PS; Quigley P; Harsanyi Z; Darke AC
Pain Res Manag; 2010; 15(3):169-78. PubMed ID: 20577660
[TBL] [Abstract][Full Text] [Related]
3. Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.
Zah V; Stanicic F; Vukicevic D; Grbic D
Pain Manag; 2024; 14(4):195-207. PubMed ID: 38939964
[TBL] [Abstract][Full Text] [Related]
4. Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch.
Stanicic F; Grbic D; Vukicevic D; Zah V
Pain Manag; 2024 Jan; 14(1):35-48. PubMed ID: 38235537
[TBL] [Abstract][Full Text] [Related]
5. The role of endogenous opioids in mindfulness and sham mindfulness-meditation for the direct alleviation of evoked chronic low back pain: a randomized clinical trial.
Khatib L; Dean JG; Oliva V; Riegner G; Gonzalez NE; Birenbaum J; Cruanes GF; Miller J; Patterson M; Kim HC; Chakravarthy K; Zeidan F
Neuropsychopharmacology; 2024 Jun; 49(7):1069-1077. PubMed ID: 37985872
[TBL] [Abstract][Full Text] [Related]
6. Opioid Exposure Negatively Affects Antidepressant Response to Venlafaxine in Older Adults with Chronic Low Back Pain and Depression.
Stahl ST; Jung C; Weiner DK; Peciña M; Karp JF
Pain Med; 2020 Aug; 21(8):1538-1545. PubMed ID: 31633789
[TBL] [Abstract][Full Text] [Related]
7. Retrospective review of the efficacy for sublingual ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model.
Johnson D; Feng L; Johnson C
Disabil Rehabil; 2024 May; 46(10):2117-2124. PubMed ID: 37259521
[TBL] [Abstract][Full Text] [Related]
8. Fatigue and Depressive Mood in Chronic Low Back Pain.
Saravanan A; Bajaj P; Matthews HL; Tell D; Starkweather A; Janusek L
Pain Manag Nurs; 2024 Jun; 25(3):225-230. PubMed ID: 38492990
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: a cross-sectional pilot study.
Richards GC; Lluka LJ; Smith MT; Haslam C; Moore B; O'Callaghan J; Strong J
Pain Rep; 2018; 3(4):e669. PubMed ID: 30123859
[TBL] [Abstract][Full Text] [Related]
10. Treatment of failed back surgery syndrome in a forty-three-year-old man with high-dose oxycodone/naloxone.
Bujedo BM
Anesth Pain Med; 2015 Apr; 5(2):e21009. PubMed ID: 25893186
[TBL] [Abstract][Full Text] [Related]
11. The impact of chronic pain on opioid addiction treatment: a systematic review protocol.
Dennis BB; Bawor M; Paul J; Varenbut M; Daiter J; Plater C; Pare G; Marsh DC; Worster A; Desai D; Thabane L; Samaan Z
Syst Rev; 2015 Apr; 4():49. PubMed ID: 25927914
[TBL] [Abstract][Full Text] [Related]
12. Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?
Veal FC; Peterson GM
Drugs Aging; 2015 Jun; 32(6):419-26. PubMed ID: 26025117
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine: revisiting the efficacy of transdermal delivery system.
Kitzmiller JP; Barnett CJ; Steiner NS; Stoicea N; Kamar N; Luzum JA; Mikulik E; Bergese SD
Ther Deliv; 2015; 6(4):419-22. PubMed ID: 25996041
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
15. Role of buprenorphine in prolonging the duration of post-operative analgesia in percutaneous nephrolithotomy: Comparison between bupivacaine versus bupivacaine and buprenorphine combination.
Nirmala J; Kumar A; Devraj R; Vidyasagar S; Ramachandraiah G; Murthy PV
Indian J Urol; 2015; 31(2):132-5. PubMed ID: 25878415
[TBL] [Abstract][Full Text] [Related]
16. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
17. Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management?
Pergolizzi JV; Köknel Talu G; Zmponga G; Erdine S; Taylor R; Ayan B; Raffa RB
Agri; 2015; 27(1):1-11. PubMed ID: 25867868
[TBL] [Abstract][Full Text] [Related]
18. Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics.
Katz NP; Mou J; Trudeau J; Xiang J; Vorsanger G; Orman C; Kim M
Pain; 2015 Jul; 156(7):1357-1365. PubMed ID: 25867124
[TBL] [Abstract][Full Text] [Related]
19. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
[TBL] [Abstract][Full Text] [Related]
20. Concluding statement - neuropharmacological basis and clinical rationale for control of transdermal buprenorphine as a step II analgesic.
Henningfield JE; Sun WZ
Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):77-9. PubMed ID: 26068437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
